Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Down 4.8 %

NASDAQ TNXP opened at $0.31 on Wednesday. The company has a market cap of $58.68 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $13.76. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business’s fifty day moving average is $0.24 and its 200 day moving average is $0.37.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, sell-side analysts expect that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.